Showing 1,241 - 1,260 results of 36,242 for search '(( 2 de decrease ) OR ( 50 ((((ms decrease) OR (a decrease))) OR (mean decrease)) ))', query time: 1.16s Refine Results
  1. 1241
  2. 1242
  3. 1243
  4. 1244
  5. 1245
  6. 1246
  7. 1247
  8. 1248

    <i>B-MOBILE</i> - A Smartphone-Based Intervention to Reduce Sedentary Time in Overweight/Obese Individuals: A Within-Subjects Experimental Trial by Dale S. Bond (588506)

    Published 2014
    “…However, few sedentary-reducing interventions exist and none have utilized smartphones to automate behavioral strategies to decrease SED. We tested a smartphone-based intervention to monitor and decrease SED in overweight/obese individuals, and compared 3 approaches to prompting physical activity (PA) breaks and delivering feedback on SED.…”
  9. 1249
  10. 1250
  11. 1251

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  12. 1252

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  13. 1253
  14. 1254
  15. 1255
  16. 1256

    BpiB09 affects the QS-dependent pyocyanin production, <i>C. elegans</i> paralysis in PAO1 and decreases AHL response in <i>A. tumefaciens</i> AHL reporter strain. by Patrick Bijtenhoorn (199146)

    Published 2011
    “…<p><b>A</b>) Decreased pyocyanin production. OD<sub>520</sub> of pyocyanin extracts from culture supernatants of <i>P. aeruginosa</i> carrying pBBR1MCS-5::<i>bpiB09</i> and empty pBBR1MCS-5. …”
  17. 1257
  18. 1258
  19. 1259

    Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and <i>De Novo</i> Lipogenesis of EGFRvIII Human Glioblastoma Cells by Jessica E. C. Jones (541168)

    Published 2017
    “…The impact of dual ACC1/ACC2 inhibition was investigated using a dual ACC1/ACC2 inhibitor as well as dual siRNA knock down on the cellular viability and metabolism of two glioblastoma multiform cancer cell lines, U87 and a more aggressive form, U87 EGFRvIII. …”
  20. 1260